Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), allowing the company to proceed with Phase 2 clinical development. This approval marks a critical milestone for the company’s lead candidate, which is designed to offer a new approach to treating multiple sclerosis (MS) by targeting the underlying neurodegenerative process rather than solely managing immune responses.
The upcoming Phase 2 trial will be a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of Lucid-MS in people with MS. Clinical and radiological measures will be used to assess outcomes. The company has begun trial start-up activities, including site selection, with patient enrollment and drug administration expected to commence as soon as possible.
Lucid-MS is a patented, first-in-class candidate that aims to provide neuroprotection by inhibiting demyelination—the process by which the protective myelin sheath around nerve fibers is damaged, a hallmark of MS. Unlike existing MS therapies that primarily modulate the immune system, Lucid-MS targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. In preclinical models, Lucid-MS has demonstrated the ability to prevent and even reverse myelin breakdown, suggesting potential for disease modification and repair. The candidate also showed a favorable safety profile and was well tolerated in prior Phase 1 trials involving healthy participants.
The FDA’s approval of the IND application is a significant step forward for Quantum BioPharma, which is focused on developing treatments for challenging neurodegenerative and metabolic disorders. The company’s pipeline includes drug candidates at various stages, with Lucid-MS being its lead compound developed through its wholly owned subsidiary, Lucid Psycheceuticals Inc. Beyond MS, the company is also exploring treatments for alcohol misuse disorders and has commercialized an over-the-counter product, unbuzzd, through a spin-off company, Unbuzzd Wellness Inc.
According to the company’s financial disclosures, Quantum BioPharma reported more than $10 million in cash, digital assets, and liquid investments as of March 31, 2026. This funding is expected to support the advancement of Lucid-MS into the next phase of clinical testing. The news of FDA clearance is likely to be of interest to patients, healthcare providers, and investors, as it underscores the potential for a novel therapeutic approach to MS that could address the underlying neurodegeneration, which is an area of high unmet need.
The company’s forward-looking statements, as outlined in its press release, include risks and uncertainties that could affect actual results, and the company has directed stakeholders to review its filings with the SEC for more details. For more information, the full press release is available at https://ibn.fm/HyWYH, and the latest news and updates regarding QNTM can be found in the company’s newsroom at https://ibn.fm/QNTM.
